As of November 7, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Vera Therapeutics, Inc. The largest reported stake is BlackRock, Inc.'s, at 7.4%. 13 filings are on record since August 14, 2025 (Schedule 13G/A, July 30, 2026).
Who owns Vera Therapeutics, Inc.?
Sell to companies like Vera Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Kynam Capital Management, LP · Sole voting: 0 · Shared voting: 2,890,059 · Sole dispositive: 0 · Shared dispositive: 2,890,059 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 3,996,044 · Sole dispositive: 0 · Shared dispositive: 4,148,786 · SCHEDULE 13G, 2026-08-07
- · Reporting person: BlackRock, Inc. · Sole voting: 5,247,811 · Shared voting: 0 · Sole dispositive: 5,340,522 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-30
- · Holder: T. Rowe Price Associates, Inc. · Percent: 6.4% · SCHEDULE 13G/A
- · Holder: Point72 Asset Management, L.P. · Percent: 1.7% · SCHEDULE 13G
Vera Therapeutics, Inc. has 13 Schedule 13D or 13G filings on record since 2025-08-14. 4 holders' latest filing reports 5% or more of class a common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 7.4% | 5,340,522 | SCHEDULE 13G/A, 2026-07-30 | 2026-06-30 |
| T. Rowe Price Associates, Inc. | 6.4% | 4,573,684 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| State Street Corporation | 5.8% | 4,148,786 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| Deep Track Capital, LP | 5.5% | 3,921,362 | SCHEDULE 13G, 2026-03-11 | 2026-03-04 |
| Fmr LLC | 4.1% | 2,885,853 | SCHEDULE 13G/A, 2026-02-05 | 2025-12-31 |
| Kynam Capital Management, LP | 4.01% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Sofinnova Venture Partners X, L.P. ("SVP X") | 4% | 2,793,987 | SCHEDULE 13D/A, 2026-03-05 | 2025-12-10 |
| Point72 Asset Management, L.P. | 1.7% | 1,229,525 | SCHEDULE 13G, 2026-04-01 | 2026-03-25 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Vera Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Vera Therapeutics, Inc. and the records around it.
Vera Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Sofinnova Venture Partners X, L.P. ("SVP X") also filed stake reports on 1 other company: Jade Biosciences, Inc. (Mar 2026)
- Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), CytomX Therapeutics, Inc. (Aug 2026), Viridian Therapeutics, Inc. (Aug 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Watch Vera Therapeutics, Inc.
Get an email when Vera Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Vera Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Vera Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vera Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,247,811 | 0 | 5,340,522 | 0 | SCHEDULE 13G/A, 2026-07-30 |
| State Street Corporation | 0 | 3,996,044 | 0 | 4,148,786 | SCHEDULE 13G, 2026-08-07 |
| Kynam Capital Management, LP | 0 | 2,890,059 | 0 | 2,890,059 | SCHEDULE 13G/A, 2026-08-14 |
| Kynam Capital Management GP, LLC | 0 | 2,890,059 | 0 | 2,890,059 | SCHEDULE 13G/A, 2026-08-14 |
| Yue Tang | 0 | 2,890,059 | 0 | 2,890,059 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Vera Therapeutics, Inc. by CUSIP 92337R101 and gives its principal executive office as 2000 Sierra Point Parkways, Suite 1200, Brisbane, CA 94005 (SCHEDULE 13G/A, 2026-08-14).
Purpose of Transaction (Item 4)
Sofinnova Venture Partners X, L.P. ("SVP X")
The Reporting Persons hold their securities of the Issuer for investment purposes. Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Persons to their respective members or limited partners. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons' review of numerous factors, including, among other things, the price levels of the Common Stock, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities, and other future developments. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-03-05
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Kynam Capital Management, LP | 5.37% | SCHEDULE 13G |
| 2025-11-14 | T. Rowe Price Associates, Inc. | 5.7% | SCHEDULE 13G/A |
| 2026-01-30 | The Vanguard Group | 5.03% | SCHEDULE 13G |
| 2026-02-05 | Fmr LLC | 4.1% | SCHEDULE 13G/A |
| 2026-02-17 | T. Rowe Price Associates, Inc. | 7.7% | SCHEDULE 13G/A |
| 2026-03-05 | Sofinnova Venture Partners X, L.P. ("SVP X") | 4% | SCHEDULE 13D/A |
| 2026-03-11 | Deep Track Capital, LP | 5.5% | SCHEDULE 13G |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-01 | Point72 Asset Management, L.P. | 1.7% | SCHEDULE 13G |
| 2026-05-15 | T. Rowe Price Associates, Inc. | 6.4% | SCHEDULE 13G/A |
| 2026-07-30 | BlackRock, Inc. | 7.4% | SCHEDULE 13G/A |
| 2026-08-07 | State Street Corporation | 5.8% | SCHEDULE 13G |
| 2026-08-14 | Kynam Capital Management, LP | 4.01% | SCHEDULE 13G/A |
Questions about who owns Vera Therapeutics, Inc.
Who owns Vera Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Vera Therapeutics, Inc.: BlackRock, Inc. (7.4%, Schedule 13G/A, filed 2026-07-30), T. Rowe Price Associates, Inc. (6.4%, Schedule 13G/A, filed 2026-05-15), State Street Corporation (5.8%, Schedule 13G, filed 2026-08-07) and Deep Track Capital, LP (5.5%, Schedule 13G, filed 2026-03-11).
Who are the largest shareholders of Vera Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Vera Therapeutics, Inc. on this page are BlackRock, Inc. (7.4%), T. Rowe Price Associates, Inc. (6.4%) and State Street Corporation (5.8%).
When did BlackRock, Inc. buy into Vera Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G/A, filed 2026-07-30, reporting 7.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Vera Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 9, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Vera Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.